Oral Semaglutide Pharmacokinetics in Healthy Subjects, Effect of Dosing Schedules
Latest Information Update: 16 May 2023
Price :
$35 *
At a glance
- Drugs Semaglutide (Primary)
- Indications Alzheimer's disease; Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 17 Mar 2023 Primary endpoint has been met, (Area under the semaglutide plasma concentration - time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,day10), as per Results published in the Clinical Pharmacokinetics
- 17 Mar 2023 Results published in the Clinical Pharmacokinetics
- 31 May 2021 Status changed from active, no longer recruiting to completed.